Isturisa: how international patients access US-sourced specialty supply

This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.

Quick orientation

Isturisa (osilodrostat) is sponsored by Recordati Rare Diseases and received first US FDA approval in 2020. It is delivered as oral, twice daily. The US label covers treatment of adult patients with Cushing disease for whom pituitary surgery is not an option or has not been curative. Mechanistically, Osilodrostat inhibits 11-beta-hydroxylase (CYP11B1), the final step in cortisol synthesis.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

US wholesale acquisition cost (WAC) is the published US specialty-distribution list price and is not the same as a single-payer negotiated price. US WAC for Isturisa typically lands in the USD 95,000 to USD 130,000 annual range depending on titrated dose. Patient out-of-pocket via cross-border supply is the US WAC plus logistics, IOR / customs, translation, and a Reserve Meds concierge fee; it is not a route to local-formulary pricing.

Mechanism of action

Osilodrostat inhibits 11-beta-hydroxylase (CYP11B1), the final step in cortisol synthesis. By blocking that enzyme, Isturisa lowers serum and urinary free cortisol toward target ranges in patients with ACTH-driven hypercortisolism. Dose titration is guided by 24-hour urinary free cortisol and clinical response.

Why Isturisa routes via cross-border NPP internationally

Cushing disease is rare and most regional formularies in MENA and South Asia still default to ketoconazole or metyrapone, both of which carry meaningful hepatotoxicity or supply-continuity issues. Isturisa is registered in the US and EU but is intermittently stocked or simply not listed in destination-country formularies; for adults who have failed pituitary surgery or who are awaiting repeat intervention, the named-patient route is often the only path to a modern 11-beta-hydroxylase inhibitor.

The patterns that produce cross-border demand for Isturisa are consistent across destination countries: meaningful registration lag relative to the US label, indication-specific dosing complexity that makes substitution clinically risky, payer denial patterns that exclude newer or expanded indications, and the global specialty distribution model in which the originator manufacturer routes specialty supply through a small number of authorized US wholesalers. Reserve Meds sits inside that authorized supply lane, not outside it.

How Reserve Meds coordinates supply

Every Isturisa case follows the same physician-led, document-first workflow:

1. The treating physician issues a prescription and clinical justification letter.
2. Reserve Meds clinical and regulatory review assesses indication fit and destination-country pathway eligibility.
3. Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
4. Supply is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability (a federal track-and-trace requirement) and unbroken chain of custody from US warehouse forward.
5. Cold-chain handling is validated where applicable; temperature is monitored end-to-end with audit logs.
6. Shipment is coordinated to the patient's treating physician or hospital pharmacy, not directly to consumers.

Reserve Meds does not handle controlled substances. We do not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are different commercial frameworks aimed at US-domiciled patients.

Common cross-border destinations

Isturisa cross-border demand concentrates in markets where US specialty supply is the most reliable path to the labeled indication. We publish destination-country deep-dives where local matrix cells exist; the rest are coordinated case-by-case on the same physician-led workflow.

Across each of these destinations, three structural patterns repeat. First, the local regulator maintains a named-patient or personal-import framework precisely so clinicians can reach a labeled US therapy for individual patients whose case cannot wait for full local registration. Second, that framework is document-driven, which means the work of cross-border access is the work of preparing a defensible clinical and regulatory dossier rather than chasing inventory. Third, the destination-country specialist (the treating physician) signs the case in; Reserve Meds operates on top of that signature, not in place of it.

Real cost picture

Annual drug cost at US WAC commonly sits between USD 95,000 and USD 130,000 for typical titrated regimens. Isturisa is oral and not cold-chain critical, so logistics cost is modest relative to biologics; customs, IOR, and translation costs apply normally. Reserve Meds quotes firm pricing after the prescribing physician dossier and ongoing labs plan are reviewed.

A formal Reserve Meds quote breaks out: drug cost at US WAC; cold-chain 3PL handling where applicable; IOR, customs, and destination-country regulatory fees; certified translation of physician documentation; and a tiered Reserve Meds concierge fee layered on the drug cost rather than per-dose. The indicative range above is for orientation; a firm quote is issued after physician documentation is reviewed.

Reserve Meds does not charge intake deposits. Patients pay the firm-quoted amount in full only after accepting the quote, with a defined refund posture for procurement failure or gross negligence as set out in the engagement documentation. Delivery or transit-failure outcomes are handled via insurance and replacement coordination rather than refund, because once a US procurement chain is committed, the drug is committed.

Manufacturer context and global distribution

Isturisa is manufactured by Recordati Rare Diseases. Like most US specialty therapies, it is routed through a narrow set of authorized specialty wholesalers under DSCSA (Drug Supply Chain Security Act) track-and-trace rules. That is the same supply lane US specialty pharmacies use; cross-border named-patient access works by attaching destination-country regulatory documentation to a shipment that originates inside that authorized lane, not by sourcing outside it. Counterfeit and parallel-trade exposure is concentrated outside that lane, which is precisely why Reserve Meds will not source from secondary or grey-market channels regardless of price.

Serial-number traceability is preserved end-to-end. Every Isturisa pack or vial carries the US wholesaler's lot and serial-number documentation forward into the destination-country regulatory submission, which is what allows the destination regulator to verify provenance on inspection.

What your physician provides

For Reserve Meds to coordinate Isturisa, the treating physician provides a treating-endocrinologist prescription, a clinical justification letter documenting Cushing disease etiology and post-surgical or non-surgical status, baseline 24-hour urinary free cortisol and electrolyte panel, an active adrenal-insufficiency monitoring plan, and license verification. Reserve Meds does not substitute for treating-physician judgment, does not prescribe, and does not advise on individual patient suitability; that is the treating physician's role.

Common questions

Is Isturisa used for all forms of Cushing syndrome?

No. The US label is limited to adult Cushing disease (ACTH-driven), specifically patients who are not surgical candidates or who have persistent disease post-surgery. Other Cushing etiologies are off-label.

How quickly does cortisol come down on Isturisa?

Cortisol can fall rapidly with titration, which is why prescribing labels emphasize monitoring for adrenal insufficiency and QT prolongation.

Does Isturisa replace pituitary surgery?

No. Pituitary surgery remains first-line for most Cushing disease. Isturisa is for patients in whom surgery is not feasible or has not achieved remission.

Can it be combined with other cortisol-lowering agents?

Combination therapy is sometimes used by endocrinology specialists but should be physician-directed and monitored closely.

Is special storage required?

Isturisa is oral and stored at controlled room temperature; standard pharmaceutical handling applies.

Indicative timing

Time-to-first-dose for Isturisa is dominated by destination-country regulatory turnaround on the named-patient or personal-import submission, not by US procurement (which is typically days, not weeks, for an authorized specialty wholesaler with serialized stock). In faster markets (UAE Ministry of Health and Prevention named-patient track, Saudi SFDA named-patient track), the regulatory clock is commonly under 4 weeks when the dossier is complete on first submission. In slower markets or where translations and additional attestations are required, the regulatory clock can extend to 6 to 10 weeks. Reserve Meds frames every Isturisa timeline as an indicative range with a defined gating event (regulator acknowledgement), not as a guaranteed delivery date.

Subsequent cycles are materially faster than the first cycle because the regulatory file, physician credentials, and import authorization are already on record. For chronic-use therapies like Isturisa, the first cycle carries the regulatory overhead; the rest is logistics.

Where Reserve Meds fits in

Reserve Meds is the named cross-border coordinator. A dedicated patient coordinator owns the case from intake through delivery, the clinical and regulatory teams handle the document chain, and a DSCSA-compliant specialty wholesaler is the source of every vial or pack. We work in service of the treating-physician relationship, not around it.

Patients deal with one named coordinator from intake through delivery. Physicians deal with a clinical-and-regulatory contact who speaks the language of the destination regulator and of US specialty pharmacy. That single-point-of-contact structure is deliberate: cross-border specialty access fails most often at the seams between parties, not inside any single step, and Reserve Meds is built to own the seams.

Next step

Submit a 60-second intake. Our clinical team will respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.

Start your case Or message us on WhatsApp